《Insight Partners：2024-2030年北美基因檢測服務市場分析與預測報告（英文版）（101頁）.pdf》由會員分享，可在線閱讀，更多相關《Insight Partners：2024-2030年北美基因檢測服務市場分析與預測報告（英文版）（101頁）.pdf（101頁珍藏版）》請在三個皮匠報告上搜索。

1、 North America Genetic Testing Services Market Market Size and Forecast(2020-2030)Regional Growth Opportunity Analysis Coverage:By Service Service TypeType(Predictive Testing,Carrier Testing,Prenatal Testing,Newborn Screening,and Others),DiseaseDisease(Cancer,Metabolic Diseases,Cardiovascular Diseas

2、es,and Other Diseases),Service ProviderService Provider(Hospital-Based Laboratories,Diagnostic Laboratories,and Others),and CountryCountry 2 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Table of Content 1.Introduction.12 1.1 The Insight Partners Research Report Guida

3、nce.12 1.2 Market Segmentation.13 2.Executive Summary.14 2.1 Key Insights.14 3.Research Methodology.15 3.1 Coverage.16 3.2 Secondary Research.16 3.3 Primary Research.16 4.North America Genetic Testing Services Market-Key Industry Dynamics.18 4.1 Key Market Drivers.18 4.1.1 Rising Prevalence of Genet

4、ic Diseases.18 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines.19 4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing.19 4.2 Market Restraints.21 4.2.1 Social and Ethical Implications of Genetic Testing.21 4.2.2 Affordability of Genetic Services.21 4.3 Market Oppo

5、rtunities.22 4.3.1 Untapped Emerging Markets in Developing Countries.22 4.4 Future Trends.22 4.4.1 Artificial Intelligence-Powered Genetic Testing.22 4.5 Impact Analysis:.23 5.Genetic Testing Services Market-North America Market Analysis.24 5.1 North America Genetic Testing Services Market Revenue(U

6、S$Mn),2022 2030.24 6.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type.25 6.1 Overview.25 6.2 North America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).25 6.3 Predictive Testing.26 6.3.1 Overview.26 3 North America Genetic Testi

7、ng Services Market,2020-2030 |The Insight Partners 6.3.2 Predictive Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).26 6.4 Carrier Testing.28 6.4.1 Overview.28 6.4.2 Carrier Testing:North America Genetic Testing Services Market Revenue and Forecast to 2

8、030(US$Million).28 6.5 Prenatal Testing.29 6.5.1 Overview.29 6.5.2 Prenatal Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 6.6 Newborn Screening.30 6.6.1 Overview.30 6.6.2 Newborn Screening:North America Genetic Testing Services Market Revenue and F

9、orecast to 2030(US$Million).30 6.7 Others.32 6.7.1 Overview.32 6.7.2 Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).32 7.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Disease.34 7.1 Overview.34 7.2 North America Genetic T

10、esting Services Market Revenue Share,by Disease,2022&2030(%).34 7.3 Cancer.35 7.3.1 Overview.35 7.3.2 Cancer:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 7.4 Cardiovascular Diseases.36 7.4.1 Overview.36 7.4.2 Cardiovascular Diseases:North America Genetic

11、Testing Services Market Revenue and Forecast to 2030(US$Million).36 7.5 Metabolic Diseases.37 7.5.1 Overview.37 7.5.2 Metabolic Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).37 7.6 Other Diseases.38 7.6.1 Overview.38 7.6.2 Other Diseases:North Americ

12、a Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).38 4 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Provider.40 8.1 Overview.40 8.2 North America Genetic

13、Testing Services Market Revenue Share,by Service Provider,2022&2030(%).40 8.3 Hospital-Based Laboratories.41 8.3.1 Overview.41 8.3.2 Hospital-Based Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).41 8.4 Diagnostic Laboratories.42 8.4.1 Overview.42

14、8.4.2 Diagnostic Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).42 8.5 Others.43 8.5.1 Overview.43 8.5.2 Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).43 9.North America Genetic Testing Services Mark

15、et-Country Analysis.44 9.1 North America.44 9.1.1 North America Genetic Testing Services Market,by Country.44 9.1.1.1 US.45 9.1.1.1.1 Overview.45 9.1.1.1.2 US:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).45 9.1.1.1.3 US:North America Genetic Testing Services Mark

16、et,by Service Type,20202030(US$Million).46 9.1.1.1.4 US:North America Genetic Testing Services Market,by Disease,20202030(US$Million).47 9.1.1.1.5 US:North America Genetic Testing Services Market,by Service Provider,20202030(US$Million).47 9.1.1.2 Canada.48 9.1.1.2.1 Overview.48 9.1.1.2.2 Canada:Nor

17、th America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).48 9.1.1.2.3 Canada:North America Genetic Testing Services Market,by Service Type,20202030(US$Million).49 9.1.1.2.4 Canada:North America Genetic Testing Services Market,by Disease,20202030(US$Million).49 9.1.1.2.5 Canada:

18、North America Genetic Testing Services Market,by Service Provider,20202030(US$Million).49 5 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3 Mexico.50 9.1.1.3.1 Overview.50 9.1.1.3.2 Mexico:North America Genetic Testing Services Market Revenue and Forecast to 203

19、0(US$Mn).51 9.1.1.3.3 Mexico:North America Genetic Testing Services Market,by Service Type,20202030(US$Million).51 9.1.1.3.4 Mexico:North America Genetic Testing Services Market,by Disease,20202030(US$Million).52 9.1.1.3.5 Mexico:North America Genetic Testing Services Market,by Service Provider,2020

20、2030(US$Million).52 10.Genetic Testing Services MarketIndustry Landscape.53 10.1 Overview.53 10.2 Growth Strategies in North America Genetic Testing Services Market.53 10.3 Organic Growth Strategies.54 10.3.1 Overview.54 10.4 Inorganic Growth Strategies.56 10.4.1 Overview.56 11.Company Profiles.57 1

21、1.1 Eurofins Scientific SE.57 11.1.1 Key Facts.57 11.1.2 Business Description.57 11.1.3 Products and Services.58 11.1.4 Financial Overview.59 11.1.5 SWOT Analysis.60 11.1.6 Key Developments.61 11.2 Exact Sciences Corp.62 11.2.1 Key Facts.62 11.2.2 Business Description.62 11.2.3 Products and Services

22、.62 11.2.4 Financial Overview.63 11.2.5 SWOT Analysis.64 11.2.6 Key Developments.65 11.3 Laboratory Corp of America Holdings.66 11.3.1 Key Facts.66 11.3.2 Business Description.66 11.3.3 Products and Services.66 6 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 11.3.4 Fi

23、nancial Overview.67 11.3.5 SWOT Analysis.68 11.3.6 Key Developments.69 11.4 23andMe Holding Co.70 11.4.1 Key Facts.70 11.4.2 Business Description.70 11.4.3 Products and Services.71 11.4.4 Financial Overview.71 11.4.5 SWOT Analysis.72 11.4.6 Key Developments.73 11.5 Ambry Genetics Corp.74 11.5.1 Key

24、Facts.74 11.5.2 Business Description.74 11.5.3 Products and Services.75 11.5.4 Financial Overview.75 11.5.5 SWOT Analysis.75 11.5.6 Key Developments.76 11.6 Quest Diagnostics Inc.77 11.6.1 Key Facts.77 11.6.2 Business Description.77 11.6.3 Products and Services.78 11.6.4 Financial Overview.78 11.6.5

25、 SWOT Analysis.79 11.6.6 Key Developments.80 11.7 Illumina Inc.81 11.7.1 Key Facts.81 11.7.2 Business Description.81 11.7.3 Products and Services.82 11.7.4 Financial Overview.82 11.7.5 SWOT Analysis.83 11.7.6 Key Developments.84 11.8 F.Hoffmann-La Roche Ltd.85 11.8.1 Key Facts.85 11.8.2 Business Des

26、cription.85 11.8.3 Products and Services.86 7 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 11.8.4 Financial Overview.86 11.8.5 SWOT Analysis.88 11.8.6 Key Developments.90 11.9 NeoGenomics Inc.91 11.9.1 Key Facts.91 11.9.2 Business Description.91 11.9.3 Products and S

27、ervices.91 11.9.4 Financial Overview.92 11.9.5 SWOT Analysis.93 11.9.6 Key Developments.94 11.10 Centogene AG.95 11.10.1 Key Facts.95 11.10.2 Business Description.95 11.10.3 Products and Services.95 11.10.4 Financial Overview.96 11.10.5 SWOT Analysis.97 11.10.6 Key Developments.98 12.Appendix.99 12.

28、1 About Us.99 12.2 Glossary of Terms.100 8 North America Genetic Testing Services Market,2020-2030 |The Insight Partners List of Tables Table 1.North America Genetic Testing Services Market Segmentation.13 Table 2.US:North America Genetic Testing Services Market,by Service Type Revenue and Forecast

29、to 2030(US$Million).46 Table 3.US:North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).47 Table 4.US:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).47 Table 5.Canada:North America Genetic Testing

30、 Services Market,by Service Type Revenue and Forecast to 2030(US$Million).49 Table 6.Canada North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).49 Table 7.Canada:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 20

31、30(US$Million).49 Table 8.Mexico:North America Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million).51 Table 9.Mexico:North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million).52 Table 10.Mexico:North America Genetic Testing

32、 Services Market,by Service Provider Revenue and Forecast to 2030(US$Million).52 Table 11.Recent Organic Growth Strategies in North America Genetic Testing Services Market.54 Table 12.Recent Inorganic Growth Strategies in the North America Genetic Testing Services Market.56 Table 13.Glossary of Term

33、s,North America Genetic Testing Services Market.100 9 North America Genetic Testing Services Market,2020-2030 |The Insight Partners List of Figures Figure 1.North America Genetic Testing Services Market Segmentation,By Country.13 Figure 2.North America Genetic Testing Services Market-Key Industry Dy

34、namics.18 Figure 3.Impact Analysis of Drivers and Restraints.23 Figure 4.North America Genetic Testing Services Market Revenue(US$Mn),2022 2030.24 Figure 5.North America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%).25 Figure 6.Predictive Testing:North America Genetic Te

35、sting Services Market Revenue and Forecast to 2030(US$Million).27 Figure 7.Carrier Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).28 Figure 8.Prenatal Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).29 Fig

36、ure 9.Newborn Screening:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).31 Figure 10.Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).33 Figure 11.North America Genetic Testing Services Market Revenue Share,by Diseas

37、e,2022&2030(%).34 Figure 12.Cancer:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).35 Figure 13.Cardiovascular Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).36 Figure 14.Metabolic Diseases:North America Genetic

38、Testing Services Market Revenue and Forecast to 2030(US$Million).37 Figure 15.Other Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).39 Figure 16.North America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%).40 Figure 17.H

39、ospital-Based Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).41 Figure 18.Diagnostic Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million).42 Figure 19.Others:North America Genetic Testing Services Mar

40、ket Revenue and Forecast to 2030(US$Million).43 10 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 20.North America:North America Genetic Testing Services Market,by Key Country Revenue(2022)(US$Million).44 Figure 21.North America Genetic Testing Services Market,B

41、y Key Countries,2022 and 2030(%).44 Figure 22.US:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).46 Figure 23.Canada:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn).48 Figure 24.Mexico:North America Genetic Testing Services Market R

42、evenue and Forecast to 2030(US$Mn).51 Figure 25.Growth Strategies in North America Genetic Testing Services Market.53 11 North America Genetic Testing Services Market,2020-2030 |The Insight Partners NOTES:The list of companies included in the scope are as per standard report format and the list can

43、be modified/expanded as per clients requirement The sequence/list of companies do not represent their current position in the market.The list of countries provided in the report are part of standard report and can be customized as per clients requirement RELATED REPORTS Newborn Genetic Testing Marke

44、t DTC Genetic Testing Market 12 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 1.Introduction 1.1 The Insight Partners Research Report Guidance The report provides qualitative and quantitative trends of North America genetic testing services market across service type,

45、disease,service provider,and country.The report starts with the key takeaways(chapter 2),highlighting the key trends and outlook of the North America genetic testing services market.Chapter 3 provides the research methodology of the study.Chapter 4 further provides PEST analysis for each region.Chap

46、ter 5 highlights the key industry dynamics in the North America genetic testing services market,including factors that are driving the market,prevailing deterrent,potential opportunities as well as future trends.Impact analysis of these drivers and restraints is also covered in this section.Chapter

47、6 discusses the North America genetic testing services market scenario,in terms of historical market revenues,and forecast till 2030.Chapter 7 to 10 discuss genetic testing services market segments by service type,disease,service provider,and countries across North America.They cover market revenue

48、forecast,and factors driving and governing growth.Chapter 11 describes the industry landscape analysis.It provides detailed description of various business activities such as market initiatives,new developments,mergers,and joint ventures globally along with a competitive landscape.Chapter 12 provide

49、s the detailed profiles of the key companies operating in the North America genetic testing services market.The companies have been profiled on the basis of their key facts,business description,products and services,financial overview,SWOT analysis,and key developments.Chapter 13,i.e.the appendix is

50、 inclusive of a brief overview of the company,glossary of terms,contact information,and the disclaimer section.13 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 1.2 Market Segmentation Table 1.North America Genetic Testing Services Market Segmentation SERVICE TYPESERVI

51、CE TYPE DISEASEDISEASE SERVICE PROVIDERSERVICE PROVIDER PREDICTIVE TESTING CANCER HOSPITAL-BASED LABORATORIES CARRIER TESTING CARDIOVASCULAR DISEASES DIAGNOSTIC LABORATORIES PRENATAL TESTING METABOLIC DISEASES OTHERS NEWBORN SCREENING OTHER DISEASES OTHERS Source:The Insight Partners Analysis,Primar

52、y Interviews,Magazines and Journals,Secondary Sources Figure 1.North America Genetic Testing Services Market Segmentation,By Country Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources The North America genetic testing services market is segmented based o

53、n service type,disease,service provider,and country.The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research.In addition,the market is also segmented on the basis of services offered by the leading participants in the industry in orde

54、r to understand widely used market specific terminologies.Thus,we have incorporated the segments of the research and have finalized the market segmentation.USCANADAMEXICONORTH AMERICA 14 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 2.Executive Summary 2.1 Key Insight

55、s OverviewMarket SegmentationMarket DynamicsRegional OverviewMarket SegmentationKey PlayersMarket DynamicsCAGR(2022-2030)15.2%Market Size 2022$1,604.32MnMarket Size 2030$4,984.25MnService TypeDisease Predictive Testing Carrier Testing Prenatal Testing Newborn Screening Others Cancer Cardiovascular D

56、iseases Metabolic Diseases Other Diseases Laboratory Corporation of America Holdings F.Hoffmann-La Roche Ltd Illumina,Inc.Quest Diagnostics Incorporated Exact Sciences Corp(Genomic Health)NeoGenomics Laboratories,Inc.Eurofins Scientific Ambry Genetics 23andMe,IncGROWTH DRIVERSFUTURE TRENDSGROWTH DRI

57、VERSFUTURE TRENDS Rising Prevalence of Genetic Diseases Increasing Awareness and Acceptance of Personalized Medicines Artificial Intelligence-Powered Genetic TestingRESTRAINTSOPPORTUNITY Social and Ethical Implications of Genetic Testing Affordability of Genetic Services Untapped Emerging Markets in

58、 Developing CountriesService Provider Hospital-Based Laboratories Diagnostic Laboratories OthersNORTH AMERICA15.2%15 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 3.Research Methodology The Insight Partners dedicated research and analysis team consist of experienced p

59、rofessionals with advanced statistical expertise in market research and consulting backgrounds in various industries including Aerospace and Defense,Automotive and Transportation,Biotechnology,Chemicals and Materials,Food and Beverages,Electronics and Semiconductor,Healthcare IT,Manufacturing and Co

60、nstruction,Medical Device,Technology,Media and Telecommunications.Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources FinalMarket sizeValidation from Primary InterviewSummation of Revenue Generated from Companies to arrive Total Market SizeRevenue Generat

61、ed by the Products and Services Offered by Companies in the Genetic Testing Service MarketFinal Market Size Break-Up To Rest Of Segmentation(i.e.,Service Type,Disease,Service Provider,and Region)Arriving at the Market Size of each Segment Validation of Number with Primary Interviews and Subject Matt

62、er Expert BOTTOM-UP ANALYSISTOP-DOWN ANALYSIS 16 North America Genetic Testing Services Market,2020-2030 |The Insight Partners The Insight Partners adheres to the codes of practice of the Market Research Society(www.mrs.org.uk)and Strategic and Competitive Intelligence Professionals(www.scip.org).Th

63、e following methodology has been followed for the collection and analysis of data presented in this report:3.1 Coverage The objective of updating“The Insight Partners”coverage is to ensure that it represents the most up-to-date vision of the industry possible.The estimated revenues of all major comp

64、anies,including private and governmental,are gathered and used to prioritize coverage.Companies which are making the news,or which are of particular interest due to their innovative approach,are prioritized.3.2 Secondary Research The research process begins with exhaustive secondary research using i

65、nternal and external sources to obtain qualitative and quantitative information relating to each Market.The secondary research sources that are typically referred to include,but are not limited to:Company websites,annual reports,financial reports,broker reports and investor presentations Industry tr

66、ade journals and other literature National government documents,statistical databases and market reports News articles,press releases and web-casts specific to the companies operating in the market NOTE:All the financials considered in Company Profiles section have been standardized to US$.This has

67、been achieved after converting the financials(for those not in US$)with respective currency exchange rates of the particular year.3.3 Primary Research“The Insight Partners”conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its data and ana

68、lysis.A typical research interview fulfils the following functions:Provides first-hand information on the market size,market trends,growth trends,competitive landscape and future outlook Validates and strengthens secondary research findings Further develops the analysis teams expertise and market un

69、derstanding 17 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Primary research involves email interactions and telephone interviews for each market,category,segment and sub-segment across countries.The participants who typically take part in such a process include,but

70、are not limited to:Industry participants:VPs,business development managers,market intelligence managers and national sales managers Outside experts:Valuation experts,research analysts and key opinion leaders specializing in the industry 18 North America Genetic Testing Services Market,2020-2030 |The

71、 Insight Partners 4.North America Genetic Testing Services Market-Key Industry Dynamics Figure 2.North America Genetic Testing Services Market-Key Industry Dynamics Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 4.1 Key Market Drivers 4.1.1 Rising Pr

72、evalence of Genetic Diseases The prevalence of genetic diseases is rising across the world and impacting the health of people at a severe level.Genetic diseases show many symptoms that are uncommon and are mostly non-curable.Most of the genetic diseases are rare and are developed due to the mutation

73、 in the genetic makeup of the people.According to The World Health Organization(WHO)2021,10 out of every 1,000 people are affected by single-gene diseases,signifying that 70 million and 80 million people worldwide are living with any one type of single-gene disease.As per the Global Genes,7,000 know

74、n rare diseases and disorders have been identified worldwide,and more are being discovered every year.According to the University of Sheffield research,300 million people are living with genetic diseases around the world.In 2022,a report by MJH Life Sciences(US)estimated that 300,000 newborns worldw

75、ide are born with sickle cell disease every year,accounting for 5%of the global population.Also,as per the study titled Sickle Cell Disease,published in August 2023,1 in 500 African Americans is affected by sickle cell disease,and 1 in 12 African Americans carry the autosomal recessive mutation.Thus

76、,the rising prevalence of genetic diseases fuels the demand for genetic testing,which in turn drives genetic testing services market growth.DROTDRIVERSRESTRAINTSOPPORTUNITIESTRENDSRising Prevalence of Genetic DiseasesIncreasing Awareness and Acceptance of Personalized MedicinesGrowing Preference for

77、 Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingAffordability of Genetic ServicesArtificial Intelligence-Powered Genetic TestingUntapped Emerging Markets in Developing Countries 19 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 4.1.

78、2 Increasing Awareness and Acceptance of Personalized Medicines Personalized medicine is the field that utilizes patients genetic and environmental data to deliver optimal healthcare.It is based on the principle that every patient is unique and requires individualistic pharmacological treatment.Sinc

79、e it is a rapidly evolving area,it is presently incorporated into several healthcare systems.The successful completion of the Human Genome Project(HGP)in 2003 and the fast-decreasing human genome sequencing costs encouraged the development of a new medical approach,which is called personalized medic

80、ine.With an expanding repository of personalized data at the molecular level,molecular diagnostics companies are exceptionally positioned to unlock value.The awareness of personalized medicine has increased since the commencement of the Precision Medicine Initiative,announced by Barack Obama in 2015

81、.Not only in the US but also in Germany,personalized medicine,better known as individualized medicine(IM),has gained more attention.By the end of 2010,The German Federal Ministry of Education and Research(BMBF)named personalized medicine as one of the six priorities.It introduced the Action Plan cal

82、led Individualized Medicine.Moreover,the 100,000 Genomes Project is also strengthening the National Health Services position as one of the most advanced healthcare systems in the world.Also,the project is consolidating the foundation for personalized medicine,and this,in turn,contributes to the gene

83、tic testing services market growth.Large-scale drug discovery is a key to increasing the viability and usefulness of personalized medicines for the diagnosis of diseases and disorders.Genomics is one of the fastest-growing divisions of medical science.It is driving a paradigm shift in the research m

84、ethodology of a disease,as well as diagnosing and treating illness.Genetic testing has been extensively used in pharmacogenomics,also known as drug-gene testing.It helps in accelerating drug discovery and its development.In January 2023,The Human Genome Project is ensuring an era of personalized hea

85、lthcare.Now,new research shows that precision prescribing using genetic testing has ultimately reached a global tipping point for adoption.Published by Cambridge University Press,the peer-reviewed research examines the maturation of critical factors required for the use of clinical genetics at scale

86、.These advancements pave the way for supporting genome-informed clinical decision-making to be established as the new standard of care.Genetically informed prescribing offers one of the realistic mechanisms to successfully reduce the overall costs of the healthcare system and improve individual pati

87、ent care.Genetic testing encourages the adoption of a personalized medicine approach by understanding the science behind the disease,the impact of treatment,and the development of therapies for specific individual characteristics.It also helps healthcare personnel make informed decisions about disea

88、se diagnosis,treatment,and prevention by utilizing genetic testing results,leading to improved patient outcomes.4.1.3 Growing Preference for Direct-To-Consumer(DTC)Genetic Testing Personalized genetic testing and treatment have long been used globally to help individuals and families learn more abou

89、t hereditary diseases.Most of the time,genetic testing is done through healthcare personnel,such as genetic counselors.Healthcare providers decide which test is needed,order the test from a test center,collect and send the DNA sample,read the test results,and share the results with the patient.Thus,

90、these tests have traditionally been ordered and interpreted in a clinical or medical research setting.In contrast,DTC genetic testing has witnessed tremendous growth in the past decade and is becoming increasingly widespread.A genetic test offered,advertised,and sold by companies directly to the con

91、sumer,without the direct involvement of a conventional healthcare system,is called DTC genetic testing.DTC genetic testing is relatively new and helps people find out about the disease-associated genes they may carry without the need for a prescription or guidance from a genetic 20 North America Gen

92、etic Testing Services Market,2020-2030 |The Insight Partners counselor or medical practitioner.Several consumers of DTC testing view it as another method of gathering medical information about themselves.Unlike other genetic tests performed in clinics or hospitals,the consumer independently initiate

93、s and completes a DTC genetic test.The public understanding and acceptance of genetic testing is gradually increasing.Additionally,there is a rise in consumers seeking customized products and experiences for the identification and addressing of unique needs.The launch of innovative products and the

94、increase in the adoption of DTC genetic testing kits have made genetic testing more accessible to people.These kits enable users to undergo personalized health management within the comfort of their homes.Key industry players are also developing DTC genetic tests and implementing special marketing e

95、fforts that positively impact sales of DTC tests.In April 2017,the US Food and Drug Administration(FDA)gave genetics company 23andMe the consent to market DNA tests evaluating the users level of risk for ten health conditions,including late-onset Alzheimers disease and Parkinsons disease.These remai

96、n the only FDA-approved DTC tests for genetic risk of infection.The brand offers specialized,evidence-based genetic screening tests that provide insights into ones health prior to the onset of symptoms.In July 2023,Quest Diagnostics,a US-based diagnostic information service provider,introduced its f

97、irst direct-consumer genetic test,Genetic Insights.The test uses next-generation sequencing to evaluate the risk for inheritable health conditions.The test inspects 36 genes using a saliva sample.It can investigate the potential risk of up to 24 genetically inheritable conditions,including breast ca

98、ncer,heart disorders,blood disorders,and sickle cell anemia.A rising number of manufacturers are providing direct-to-consumer genetic testing that covers various health conditions and traits.The increasing demand for direct-to-consumer genetic testing products to learn about the genetic makeup and a

99、ssess the risk of developing hereditary conditions for early disease detection or prevention drives the market.21 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 4.2 Market Restraints 4.2.1 Social and Ethical Implications of Genetic Testing Genetic testing is poised to

100、play an important role in the practice of obstetrics and gynecology.Physicians are required to become familiar with the presently accessible collection of genetic tests and their limitations to guarantee patients the utmost quality of care.However,the knowledge of genetic risks can result in potenti

101、al social and psychological consequences for the people undergoing such tests.Socially,knowledge from genetic tests may lead to stigmatization and judgment within the community.Refusing to undergo genetic testing,as well as choosing to undergo genetic testing,can both lead to discrimination and stig

102、matization,depending on the prevalent public standards concerning acceptance and use of the technology.Privacy and security concerns also arise as the availability and commercialization of personal genetic data can lead to unauthorized access or misuse of sensitive information.The storage of genetic

103、 testing data and registries of patients generates concern,given that the results can negatively impact the family members.In addition,lack of informed consent can lead to adverse reactions,such as increased anxiety and unnecessary preventive measures during the disclosure of genetic test results.La

104、ck of proper counseling regarding the information about genetic risk and choices regarding genetic testing and its management can cause potential psychological distress.Therefore,the reluctance of patients to prefer genetic testing due to the social and ethical stigma impedes market growth.4.2.2 Aff

105、ordability of Genetic Services At present,genetic services are expensive and,therefore,not accessible to all.Genetic research is presently underrepresented in health research;however,studies are being conducted to establish the feasibility of such services.Present inequalities in the affordability a

106、nd feasibility of genetic services are a cause of concern for the WHO and other prominent international organizations that are centered around public health and development concerns.According to The National Library of Medicine,the average cost of genetic testing can range from less than US$100 to o

107、ver US$2,000,depending on the complexity and nature of the genetic test.In several cases,health insurance plans cover the cost of the tests when professionals recommend it.Health insurance providers vary greatly in their policies and coverage.In addition,for people who dont have insurance,the cost o

108、f these tests becomes a significant hurdle.For people without insurance seeking more specialized genetic testing,such as whole genome sequencing or advanced health risk prediction tests,the costs rise greatly.On average,these tests can cost between US$1,000 to US$2,500.The cost of the test also incr

109、eases if more than one test is needed or if multiple family members need to be tested to obtain a significant result.For newborn screening,costs differ as per the state.Several states cover part of the overall cost,although most charge a fee of US$30 to US$150 per infant.Various factors,including th

110、e type of test,the complexity of analysis,and laboratory processing fees,influence the cost of these tests.Thus,the high costs,along with its affordability in emerging economies,restrain the market growth.22 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 4.3 Market Opp

111、ortunities 4.3.1 Untapped Emerging Markets in Developing Countries Emerging countries such as China,India,Brazil,and Mexico offer significant growth opportunities to market players.The high growth can majorly be attributed to the increasing public healthcare expenditure,improving healthcare infrastr

112、ucture,and the presence of a large target patient population.The need for genetic testing has also increased owing to a rise in awareness of genetic disorders in developing economies and their early diagnosis.The quality and availability of genetic services may differ between high-income countries a

113、nd low-to middle-income countries.For instance,in the US,Australia,Canada,the UK,and other European countries,genetic services are well-advanced,established,and extensive.These services include newborn screening,carrier identification screening,and prenatal diagnosis.Yet,in many high-income countrie

114、s,genetic services that are offered in multiple settings still need improved systems of assessment.The ease and applicability of genetic testing procedures have benefitted R&D activities in developing regions worldwide.Major market players are focusing on strategies and initiatives,such as agreement

115、s,collaborations,partnerships,and expansions,to improve their product availability,accessibility,and distribution networks in these countries,as it will help them address the growing need for early diagnosis and treatment.For instance,in 2022,in an effort to advance personalized healthcare throughou

116、t Latin America,Nordic Group,a leader in nutrigenomics,has partnered with a Mexican laboratory to manage its DNAlife genetic testing platform.Through the partnership,Vitage Lab will oversee the nationwide training of medical professionals in the usage of Nordic Groups DNAlife genetic testing platfor

117、m and distribute it.In addition,rising consumer awareness regarding DTC genetic tests in developing economies offers growth opportunities to the DTC industry.Therefore,emerging markets in developing countries are expected to offer significant opportunities to the players operating in the market and

118、boost the market growth during the forecast period.4.4 Future Trends 4.4.1 Artificial Intelligence-Powered Genetic Testing As of 2018,there were 75,000 genetic tests available in the market,with nearly ten new tests entering the market every day.As per the study Trends in Availability of Genetic Tes

119、ts in the United States,20122022,published in 2023,129,624 and 197,779 genetic tests in the US and globally,respectively,have been made accessible and submitted to the genetic testing registry as of November 2022.These tests have been extended from single-gene tests to panels that look at multiple g

120、enes.Whole-genome sequencing and now whole-exome sequencing have also become more popular.To solve the growing problem of health data exhaust,the field of medicine is increasingly revolving around enhanced clinical tools,such as artificial intelligence(AI)and machine learning,which have been mention

121、ed as a way to improve the acceptance of genomic medicine.Today,many companies have turned to machine learning to process the vast amount of data needed to correctly analyze and understand clinical data in fields such as radiology and cardiology.Many of the consumer-facing genetic testing technologi

122、es that are available in the market are using machine learning or AI to function.In numerous ways,genetic testing of diseases is the perfect field for machine learning because of the vast volumes of data that these programs need to struggle with.For example,working on the human genome includes readi

123、ng billions of bits of information,and prior to the introduction of machine learning,many of these tasks were pretty tricky.AI offers great potential when it comes to analyzing genetic data and supporting clinical specialists in making diagnoses.Google has a program called Deep Variant that can now

124、be used to plot the human genome thoroughly and can be used on the full range of a persons genetic information.Moreover,agencies such as the National Institutes of Health are 23 North America Genetic Testing Services Market,2020-2030 |The Insight Partners working on ways through which machine learni

125、ng and AI can add to a better understanding of genetics and genomics.Furthermore,Blueprint Genetics is using AI in clinical interpretation.Machine learning and AI are acting as a catalyst for faster and more diverse improvement in genetic research and engineering.These tools are simple to integrate

126、and extremely scalable,putting genetic laboratories in a unique position to scale their operations and match the fast growth of the genetic testing field.Thus,through the successful integration of these tools,clinicians will be able to diagnose rare genetic diseases more efficiently and effectively,

127、bringing hope to the millions of people affected by them globally.4.5 Impact Analysis:The following figure depicts the impact of factors driving and restraining the North America genetic testing services market.The factors driving the market growth include increasing prevalence of genetic diseases,i

128、ncreasing awareness and acceptance of personalized medicines,and growing preference for direct-to-consumer genetic testing.However,social and ethical implications of genetic testing and affordability of genetic services hinders the market growth.Figure 3.Impact Analysis of Drivers and Restraints Sou

129、rce:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources Rising Prevalence of Genetic DiseasesGrowing Preference towards for Direct-To-Consumer Genetic TestingSocial and Ethical Implications of Genetic TestingLOWMEDIUMHIGHIncreasing Awareness and Acceptance of Pe

130、rsonalized Medicines 24 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 5.Genetic Testing Services Market-North America Market Analysis The North America genetic testing services market in North America is segmented into the US,Canada,and Mexico.In 2022,the US held the

131、largest market share in this region and is expected to continue its dominance during 20222030.The North America genetic testing services market in North America is expected to grow due to the rising number of cancer patients,increasing government funding,and rising incidence of genetic diseases amon

132、g the population in the US and Canada during recent years.Moreover,increasing focus on advanced method incorporation in healthcare,government and private initiatives for the promotion of precision medicine,and massive funds from government and private bodies for genetic research contribute to except

133、ional revenue generation for the North America genetic testing services market in North America.5.1 North America Genetic Testing Services Market Revenue(US$Mn),2022 2030 The North America genetic testing services market is expected to reach US$4,984.25 million by 2030 from US$1,604.32 million in 20

134、22.The market is estimated to grow at a CAGR of 15.2%from 2022 to 2030.The factors driving the market growth include the increasing prevalence of genetic diseases,growing preference for direct-to-consumer genetic testing,and increasing awareness and acceptance of personalized medicines.However,socia

135、l and ethical implications of genetic testing and affordability of genetic services restrain the growth of the market.Figure 4.North America Genetic Testing Services Market Revenue(US$Mn),2022 2030 Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 1,277

136、.491,430.911,604.321,809.842,054.232,345.832,695.073,114.963,621.834,236.264,984.2512.0%12.1%12.8%13.5%14.2%14.9%15.6%16.3%17.0%17.7%0.0%2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%18.0%20.0%2020202120222023202420252026202720282029203001,0002,0003,0004,0005,0006,0002020-2030Historical YearBase YearForecast

137、Year 25 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Service Type 6.1 Overview The North America genetic testing services market,by service type,is segmented into predictive testing,carri

138、er testing,prenatal testing,newborn screening,and others.In 2022,the predictive testing segment held the largest share of the market and is expected to register the highest CAGR in the market during the coming years.6.2 North America Genetic Testing Services Market Revenue Share,by Service Type,2022

139、&2030(%)Figure 5.North America Genetic Testing Services Market Revenue Share,by Service Type,2022&2030(%)Source:The Insight Partners Analysis The predictive testing segment led the market in 2022 with a share of 39.7%and is expected to retain its dominance during 20222030 by accounting for 43.4%of t

140、he total market by 2030.39.7%24.2%12.8%15.2%8.1%2022Predictive TestingCarrier TestingPrenatal TestingNew-born ScreeningOthers43.4%24.9%12.1%15.4%4.2%2030 26 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.3 Predictive Testing 6.3.1 Overview Predictive genetic testing

141、examines any genetic changes or mutations that are linked to disease.These tests are done prior to an individual displaying any signs of a disease.Predictive testing can be helpful to people who have a family history of a treatable genetic disorder and display no signs of illness.This testing can id

142、entify mutations that increase an individuals risk of developing disorders with a genetic foundation,such as certain types of cancer.An example is testing for the BRCA1 and BRCA2 gene variants(altered genes)linked with an increased risk of breast cancer.The results of predictive testing can provide

143、information about the probability of developing a specific disorder and help in making decisions about medical care.Breast cancer is one of the most common types of cancer in the US.A report published by Breastcancer.org in January 2022 stated that 287,850 new incidences of invasive breast cancer,al

144、ong with 51,400 new cases of noninvasive breast cancer,were detected in women in the US in 2022.Similarly,in 2022,according to the Canadian Cancer Society,28,600 Canadian women were diagnosed with breast cancer,accounting for nearly 25%of all new cancer cases in women.The increasing prevalence of mu

145、ltiple types of cancer is driving the market for the predictive testing segment.The increasing demand for genetic counseling is expected to drive the market for predictive testing as more people understand the importance of genetics in disease etiology.The ongoing advancements and upgrading of platf

146、orms to improve the efficiency of genome analysis techniques are expected to boost the adoption of predictive testing solutions.A growing focus on reducing the growing healthcare burden of rare genetic diseases and rapid integration of technologies such as artificial intelligence and machine learnin

147、g will enhance product development and fuel the need for predictive testing to assess and prevent future complications arising from diseases effectively.6.3.2 Predictive Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Predictive testing segment was value

148、d at US$637.06 million in 2022 and is expected to reach US$2,165.31 million by 2030.The growth rate of this segment is projected to be 16.5%during 20222030.27 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 6.Predictive Testing:North America Genetic Testing Servi

149、ces Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 495.46561.58637.06727.07834.79964.211,120.321,309.421,539.441,820.462,165.31202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 28 North

150、 America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.4 Carrier Testing 6.4.1 Overview Carrier testing is a kind of genetic test that can tell whether one carries a gene for certain genetic disorders or not.When it is done before or during pregnancy,it helps to find out the chan

151、ces of having a child with a genetic disorder.Carrier testing is used to identify people carrying one copy of a gene mutation(a genetic change)that,when present in two copies,results in a genetic disorder.Carriers generally do not have symptoms or have only mild symptoms.They often are unaware that

152、they have a gene for a disorder.Carrier screening is offered for a limited number of diseases,including cystic fibrosis,sickle cell disease,fragile X syndrome,and TaySachs disease.A few of these disorders occur commonly in certain ethnic groups.For example,sickle cell disease occurs most frequently

153、in African Americans.TaySachs disease is most common in Eastern or Central European Jewish people,French Canadian people,and Cajun descent.Although,anyone can have one of these disorders as they are not restricted to these groups.With the increasing prevalence of genetic diseases caused by chromosom

154、e and gene mutations,carrier testing has grown exponentially.The majority of cases of genetic mutations are due to preexisting conditions,a family history of abortion,or congenital disabilities.Pregnant women often undergo carrier screening in order to determine the risk of transmitting a specific g

155、enetic disease to their progeny.In addition,the increasing recognition of the importance of early diagnosis and screening of gene illness fuels the need to develop strategies to tackle these diseases.6.4.2 Carrier Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$

156、Million)Carrier testing segment was valued at US$387.74 million in 2022 and is expected to reach US$1,241.51 million by 2030.The growth rate of this segment is projected to be 15.7%during 20222030.Figure 7.Carrier Testing:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$

157、Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 306.42344.52387.74439.07500.25573.42661.28767.19895.401,051.241,241.51202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 29 North America Genetic Testing Services Market,2020-203

158、0 |The Insight Partners 6.5 Prenatal Testing 6.5.1 Overview Genetics can have an impact on the color of a babys eyes and hair and can also result in the development of some birth defects or genetic disorders.This testing helps to detect abnormalities in a fetuss genes or chromosomes and syndromes be

159、fore birth.Thats why women are regularly offered a wide range of prenatal genetic testing in the first and second trimesters of pregnancy to evaluate the problems in their unborn babies.According to the WHO,congenital disabilities affect 8 million newborns every year.Nine out of every ten children a

160、re born with a serious birth defect in low-and middle-income countries.Congenital disabilities can occur at any point through the pregnancy;however,most of them occur during the first trimester when the babys organs are formed.With the ease of availability,pregnant females and their families are sho

161、wing increased adoption toward the conduction of prenatal tests.According to the National Human Genome Research Institute(US),since December 2016,the adoption of prenatal genetic tests has notably increased with the introduction of noninvasive prenatal tests for the diagnosis of a range of genetic d

162、isorders in females.The segment is expected to show rapid growth in the coming years owing to the increasing prenatal testing and screening in developed regions such as North America and Europe and the new genetic tests introduced by the players in the market.For instance,in February 2019,Invitae Co

163、rporation,one of the leading genetics companies,introduced a noninvasive prenatal screening that offers in-depth genetic information about the child in early pregnancy.The company announced the launch in Las Vegas in conjunction with the Society for Maternal-Fetal Medicine meeting.6.5.2 Prenatal Tes

164、ting:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Prenatal testing segment was valued at US$205.00 million in 2022 and is expected to reach US$601.15 million by 2030.The growth rate of this segment is projected to be 14.4%during 20222030.Figure 8.Prenatal Tes

165、ting:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 165.57184.15205.00229.63258.78293.40334.66384.01443.27514.70601.15202020212022202320242025202620272028202920302020-2030Historical YearB

166、ase YearForecast Year 30 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.6 Newborn Screening 6.6.1 Overview A newborn screening test looks for various developmental,genetic,and metabolic disease disorders in the newborn.Newborn screening allows measures to be taken be

167、fore symptoms develop.Most of these illnesses are extremely rare but can be treated if detected early.The offspring has a high risk of having genetic diseases in cases where the parents have another child with a genetic disease,a family history of a genetic disorder,or if either of a parent has a ch

168、romosomal abnormality.Early testing for these conditions allows physicians and parents to take timely measures to manage,treat,or intervene in disease progression,allowing the baby to lead a healthy,normal life.All babies must be screened at birth,irrespective of whether they look healthy or not,sin

169、ce there can be conditions that may not manifest in ways that make the child look unhealthy.In the US,all states require newborns to be tested for specific genetic and metabolic defects that cause specific conditions.As per the Newborn Screening Contingency Plan Version II,over 12,000 infants of nea

170、rly four million babies born in the US each year are diagnosed with detectable and treatable disorders.Most babies are screened at birth by state newborn screening programs to detect certain conditions that may threaten their long-term health.If diagnosed timely,conditions such as congenital hypothy

171、roidism,sickle cell disease,or phenylketonuria can be successfully managed or treated to prevent severe and lifelong health consequences.These genetic diseases are also responsible for infant mortality worldwide.For instance,according to the World Health Organization 2023,an estimated 240,000 newbor

172、ns across the world die within 28 days of birth every year due to congenital disorders.According to the Centers for Disease Control and Prevention(CDC)statistics,congenital disabilities affect every 1 in 33 infants born in the US.The same source further states that chromosomal abnormalities such as

173、Down syndrome are the most common chromosomal disorder that affects 1 in 700 babies born in the US.This means that 6,000 infants in the US have Down Syndrome yearly.Thus,the increasing prevalence of genetic diseases among infants surges the demand for newborn genetic tests,thus contributing to the g

174、rowth of the North America genetic testing services market.6.6.2 Newborn Screening:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Newborn screening segment was valued at US$243.95 million in 2022 and is expected to reach US$766.08 million by 2030.The growth rat

175、e of this segment is projected to be 15.4%during 20222030.31 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 9.Newborn Screening:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Int

176、erviews,Secondary Sources 193.73217.29243.95275.57313.20358.15412.02476.85555.19650.24766.08202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 32 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 6.7 Others 6.7.1 Overview The others

177、 segment is comprised of preimplantation testing and pharmacogenomics.These tests are performed to screen for genetic disorders.Pharmacogenomics testing is a type of genetic test that is used to identify the right medication for a person.Pharmacogenomics is one of the key emerging trends in the fiel

178、d of medical science,which significantly impacts the drug development process.With the use of pharmacogenomics,target identification by drugs has become comparatively easy,which confirms much higher chances of success for the approval of drugs.Clinical pharmacogenetic testing has progressively becom

179、e available for healthcare providers,comprising some academic medical center programs that support pre-emptive pharmacogenetic testing earlier to patients being prescribed certain medications.Although most pharmacogenetic programs are currently involved in adult patient populations,pharmacogenetic t

180、esting will likely have service for the pediatric population as childhood adverse drug reactions(ADRs)account for 16.5%of all ADR-related emergency visits in the US.Currently,various ongoing initiatives of pharmacogenomics implementation have been launched in the US,Europe,and Asia.In the US,27 inst

181、itutions are involved in programs that are applying pharmacogenomics,some of which have been using it for over ten years.In 2007,a wide network of several associations was introduced with the creation of the Electronic Medical Records and Genomics(eMERGE)Network.Afterward,they started a study named

182、eMERGE-PGx together with the Pharmacogenomics Research Network(PGRN),with the aim of testing genetic variation in 82 pharmacogenes through targeted sequencing.Moreover,since September 2010,with the Vanderbilt Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment program(PREDICT),more

183、 than 10,000 patients have undergone preemptive,panel-based pharmacogenomic testing.In 2011,PGRN also commenced the Translational Pharmacogenetics Program to assess PGx implementation in routine care by identifying barriers and developing solutions.Moving ahead to Asia,the Southeast Asian Pharmacoge

184、nomics Research Network(SEAPharm)platform was introduced by five Asian countries(Korea,Indonesia,Malaysia,Taiwan,and Thailand)to conduct pilot studies of adverse drug effects and develop strategies modified for Asian populations,which could guide drug usage and prove useful in disease prediction and

185、 diagnosis.Pharmacogenomics has also found diseases in the cure of cancer patients by anticipating the possible changes in drug response,efficacy,resistance,and toxicity of the chemotherapeutic and targeted immune biological agents.Therefore,pharmacogenomics for cancer therapy has achieved a number

186、of important discoveries in the existing cancer treatment,thereby driving market growth.Preimplantation genetic testing is also for couples who are at risk of having a child with a specific genetic or chromosome disorder,e.g.,cystic fibrosis or sickle cell disease.In this procedure,egg cells are rem

187、oved from the womans ovaries and fertilized with sperm cells outside the body.The fertilized embryos develop for three days,and subsequently,one or two cells are removed from each embryo.The genetic material(DNA and chromosomes)from the cells is tested for the genetic disorder in the family history.

188、One or two of the unaltered embryos are then relocated into the mothers womb(uterus).If the pregnancy is successful,the baby will not be affected by the disorder it was tested for.6.7.2 Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was va

189、lued at US$130.56 million in 2022 and is expected to reach US$210.20 million by 2030.The growth rate of this segment is projected to be 6.1%during 20222030.33 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 10.Others:North America Genetic Testing Services Market

190、Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 116.31123.37130.56138.50147.21156.66166.79177.49188.54199.62210.20202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 34 North America Genetic Test

191、ing Services Market,2020-2030 |The Insight Partners 7.North America Genetic Testing Services Market Revenue and Forecast to 2030 by Disease 7.1 Overview The North America genetic testing services market,by disease,is segmented into cancer,cardiovascular diseases,metabolic diseases,and other diseases

192、.In 2022,the cancer segment held the largest share of the market and is anticipated to grow at the highest CAGR during the coming years.7.2 North America Genetic Testing Services Market Revenue Share,by Disease,2022&2030(%)Figure 11.North America Genetic Testing Services Market Revenue Share,by Dise

193、ase,2022&2030(%)Source:The Insight Partners Analysis The cancer segment led the market in 2022 with a share of 45.1%and is expected to retain its dominance during 20222030 by accounting for 49.4%of the total market by 2030.45.1%22.4%19.1%13.4%2022CancerCardiovascularDiseasesMetabolic DiseasesOther D

194、iseases49.4%23.5%17.7%9.5%2030 35 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.3 Cancer 7.3.1 Overview Genetic testing is a potential tool to identify individuals who are at higher risk for developing certain cancers because of family history.Genetic tests are avai

195、lable to examine inherited variants and alterations in the DNA sequence,which could result in excessive cell growth and can cause tumors or cancer.For example,genetic testing for the detection of PALB2(linked with increased risks of breast and pancreatic cancers),BRIP1(ovarian cancer),RAD51C and RAD

196、51D(ovarian cancer),and CHEK2(breast and colorectal cancers).The worldwide growing prevalence of various cancers,such as breast,lung,and bowel,are the major drivers of this segment.According to the American Cancer Society,1,898,160 new cancer cases and 608,570 cancer deaths were anticipated to occur

197、 in the US in 2021.Nearly 10%to 20%of all cancers are related to gene mutations that are inherited or passed down through the family.Approximately 510%of cancers diagnosed in the US are associated with hereditary cancer syndromes.During the last decade,efforts have been made by the public health,med

198、ical,and scientific community to update the public about ideas such as family history,hereditary cancer risk,and genetic testing for inherited cancer.For instance,CDCs Cancer Genomics Program develops best practices in education,surveillance,and policy and systems transformation approaches.It establ

199、ishes an evidence base for the application of family history and cancer genomics in public health practice.Other factors that might impact cancer genetic testing awareness include DTC marketing of cancer genetic testing and federal regulations of genetic information,high awareness regarding the avai

200、lability of quality cancer diagnostics tests,and the escalating incidence of hereditary diseases.In addition,a growing number of companies providing genomic profiling services for health assessment,including cancer risk prediction,and the availability of numerous laboratories offering genetic testin

201、g for BRCA,and other genes associated with hereditary breast,ovarian,and related cancers propel the market for the segment.7.3.2 Cancer:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cancer segment was valued at US$723.77 million in 2022 and is expected to reac

202、h US$2,460.90 million by 2030.The growth rate of this segment is projected to be 16.5%during 20222030.Figure 12.Cancer:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 562.72637.92723.77826

203、.13948.631,095.781,273.261,488.221,749.672,069.042,460.90202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 36 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.4 Cardiovascular Diseases 7.4.1 Overview Heart diseases are a promine

204、nt cause of death worldwide and often run in families.In addition,as per the World Heart Federation 2023,rare cardiovascular diseases(CVD)are common,affecting 5%of the global population.There are over 6,000 known rare diseases,a handful of which impact the heart and circulatory system.And 83%of phys

205、icians agree that genetic testing is useful in finding the diagnosis.Certain CVD conditions,such as cardiomyopathy,arrhythmia,and connective tissue disease,are caused by a single harmful DNA variation(or mutation).However,others,such as heart attack and high blood pressure,are usually caused by the

206、combined effect of many smaller-impact DNA variations.More than 1 in 200 people have an inherited form of CVD disease,but most are unaware of it.Patients with an inherited cardiovascular condition display few or no symptoms but still face significant risk of heart disease,including sudden cardiovasc

207、ular arrest.Genetic testing can help save lives and is informative and useful for the clinical management and treatment of numerous inherited CVDs.7.4.2 Cardiovascular Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Cardiovascular diseases segment was v

208、alued at US$359.90 million in 2022 and is expected to reach US$1,169.40 million by 2030.The growth rate of this segment is projected to be 15.9%during 20222030.Figure 13.Cardiovascular Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight P

209、artners Analysis,Primary Interviews,Secondary Sources 283.41319.22359.90408.27466.00535.13618.25718.60840.24988.321,169.40202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 37 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.5 Me

210、tabolic Diseases 7.5.1 Overview Diagnosis through genetic testing can strongly help discover the cause of persistent,often debilitating,undiagnosed signs in individuals suffering from suspected genetic metabolic disease disorders.With knowledge of variants in over 1,250 metabolic disease disorders g

211、enes,the rapid testing and experience of metabolic diseases can help to diagnose and manage the patients metabolic disease disorders quickly and correctly.Ultimately,this can provide new insights into treatment choices and the probability of passing the inherited condition on to the offspring or the

212、 presence of it elsewhere in the extended family.CentoICU is a comprehensive next-generation sequencing panel that includes genes explicitly chosen for the genetic testing of extremely ill newborns and children under 24 months in intensive care units.In addition,Prevention Genetics offers a wide var

213、iety of genetic testing for inherited metabolic disease disorders,also known as inborn errors of metabolism.Panels specific to one disorder are available,as well as comprehensive metabolic diseases panels that cover broader phenotypic features or groups of similar disorders are also offered,includin

214、g tests for hyperammonemia(37 genes),metabolic diseases hypoglycemia(38 genes),and metabolic diseases myopathies,rhabdomyolysis,and exercise intolerance(83 genes).Over the past year,the company has started to offer several new tests related to these metabolic disorders,and many of the existing panel

215、s have been updated to include more genes and increase clinical sensitivity.7.5.2 Metabolic Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Metabolic diseases segment was valued at US$305.81 million in 2022 and is expected to reach US$881.42 million by

216、2030.The growth rate of this segment is projected to be 14.1%during 20222030.Figure 14.Metabolic Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 247.92275.22305.81341.87384.50435.

217、03495.16566.94652.96756.44881.42202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 38 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 7.6 Other Diseases 7.6.1 Overview The others segment by disease comprises Duchenne Muscular Dyst

218、rophy(DMD),Thalassemia,Huntingtons Disease,and Fragile X Syndrome,among others.Genetic mutations that cause DMD fail to produce dystrophin protein.Recessive diseases caused by alterations in genes on the X chromosome include DMD and fragile X syndrome.Genetic testing is used to diagnose Duchenne,to

219、access mutation-specific therapies,and for family planning.For Duchenne,the dystrophin gene is examined to detect the presence of any changes or mutations that can inhibit the gene from working properly.Genetic testing is generally performed on a blood or saliva sample.A thalassemia is a group of in

220、herited,genetic blood disorders that occur when the production of hemoglobin is disrupted.The disease is passed to children by parents carrying the mutated thalassemia gene.A kid who inherits one mutated gene is a carrier,and most carriers lead a completely normal and healthy life.At the same time,a

221、 child who inherits two thalassemia trait genes,i.e.,one from each parent,will have the disease.A child of two carriers has a 25 percent chance of developing the disease and a 50 percent chance of being a carrier.Thus,in such cases,genetic testing is helpful in detecting and diagnosing thalassemia.C

222、urrently,two major approaches are used in DNA diagnosis and study of genetic disease,namely direct tests and indirect tests(linkage analysis).Direct tests are being conducted for thalassemia and DMD.Carrier testing can be conducted for X-linked recessive disorders,such as DMD or fragile X syndrome.I

223、n these cases,the mother of an affected child with no other affected relatives may desire carrier testing to confirm whether the disease is a heritable trait or a new mutation.Many diseases may become apparent only in middle age or later.Predictive or presymptomatic testing and screening can provide

224、 symptoms that people may later develop these disorders.In some cases,a family history of a monogenic disorder in a relative informs other members of the family that they are at high risk for developing the disease.Suitable genetic testing can help to resolve whether the mutant gene is present or no

225、t.Examples include Huntingtons disease.7.6.2 Other Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Other diseases segment was valued at US$214.83 million in 2022 and is expected to reach US$472.53 million by 2030.The growth rate of this segment is proje

226、cted to be 10.4%during 20222030.39 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 15.Other Diseases:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 18

227、3.44198.55214.83233.57255.11279.89308.40341.20378.97422.46472.53202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 40 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.North America Genetic Testing Services Market Revenue and Fore

228、cast to 2030 by Service Provider 8.1 Overview The North America genetic testing services market,by service provider,is segmented into hospital-based laboratories,diagnostic laboratories,and others.In 2022,the hospital-based laboratories segment held the largest share of the market and is estimated t

229、o grow at the highest CAGR during 20222030.8.2 North America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Figure 16.North America Genetic Testing Services Market Revenue Share,by Service Provider,2022&2030(%)Source:The Insight Partners Analysis The hospital-based lab

230、oratories segment led the market in 2022 with a share of 62.7%and is expected to retain its dominance during 20222030 by accounting for 67.4%of the total market by 2030.62.7%26.7%10.6%2022Hospital-BasedLaboratoriesDiagnostic LaboratoriesOther End Users67.4%27.6%5.0%2030 41 North America Genetic Test

231、ing Services Market,2020-2030 |The Insight Partners 8.3 Hospital-Based Laboratories 8.3.1 Overview Hospital-based laboratories are genetic testing service providers that operate within a hospital setting.For extremely specialized tests,samples may go to a research laboratory.Nearly all hospitals con

232、tain a laboratory,which is commonly proportionate in size to the population it serves.The hospitals process hundreds of samples in very les time.Tests that are performed include those needed in emergencies,such as markers for heart attack and tests where results are required rapidly for patient care

233、.They may also offer carrier testing to determine if an individual is carriers of certain genetic conditions that can be passed on to their children.Hospital laboratories can be segmented by type of testing and staffed by personnel trained in particular specialties.For instance,some sections can foc

234、us on microbiology,hematology,chemistry,and blood banking.At the same time,some units may perform highly specialized genetic tests using electron microscopy and immunohistochemistry,and others can focus on surgical pathology and cytology,which are all linked with the investigation of cell and tissue

235、 structure.The market growth for the segment can be due to the compulsory newborn screening for genetic disorders and the growing prevalence of cancer in many regions.Seattle Childrens Hospital in Washington,Wyoming,Alaska,Montana,and Idaho(WWAMI)region provides comprehensive genetic testing and con

236、sultative services to healthcare workers and families.Their genetics laboratories consist of molecular genetics,cytogenetics,biochemical genetics,and a research and development laboratory devoted to bringing the most existing and specific research tests into the clinical field.Overall,these laborato

237、ries play a crucial role in helping to diagnose genetic disorders,guide treatment decisions,and improve patient outcomes.8.3.2 Hospital-Based Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Hospital-based laboratories segment was valued at US$1,005.

238、93 million in 2022 and is expected to reach US$3,356.93 million by 2030.The growth rate of this segment is projected to be 16.3%during 20222030.Figure 17.Hospital-Based Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Anal

239、ysis,Primary Interviews,Secondary Sources 786.28888.951,005.931,145.251,311.781,511.591,752.282,043.412,397.022,828.393,356.93202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 42 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.

240、4 Diagnostic Laboratories 8.4.1 Overview Diagnostics laboratories are independent entities that provide all the diagnostic tests,screening tests,and others to the patient.These centers may be found attached to a private or public hospital.The tests performed in the diagnostic centers are obtained ea

241、rlier than hospitals.The diagnostic centers also offer packages for whole-body check-ups that are cost-effective for the patients.Tests such as cell-free fetal DNA testing,triple or quadruple screening tests,sequential screening,and others require advanced techniques,equipment,and skilled labor.Howe

242、ver,some of the hospitals and clinics do not have all the required equipment and techniques for efficient diagnosis.Therefore,various hospitals and clinics prefer to outsource tests to diagnostics centers.The diagnostics centers are well equipped and offer better results for the tests performed for

243、diseases and health conditions.The diagnostic centers provide multiple tests under one roof and offer all the prenatal diagnostics services such as screening,imaging,blood tests,chorionic villus sampling,and amniocentesis.Thus,it becomes easier for people to undergo genetic testing in such facilitie

244、s.The growing partnerships and collaboration of diagnostic laboratories with genetic testing companies and the rise in the incidences of genetic diseases across the world are anticipated to offer growth to the market.For instance,Thermo Fisher Scientific allows laboratories to perform different gene

245、tic research and genetic testing by offering technologies such as NGS and quantitative PCR.8.4.2 Diagnostic Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Diagnostic laboratories segment was valued at US$428.56 million in 2022 and is expected to re

246、ach US$1,378.01 million by 2030.The growth rate of this segment is projected to be 15.7%during 20222030.Figure 18.Diagnostic Laboratories:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 33

247、8.32380.60428.56485.55553.50634.79732.44850.20992.801,166.211,378.01202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 43 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 8.5 Others 8.5.1 Overview The others segment by service prov

248、ider comprises academic and research institutions,pharmaceutical and biotechnology companies,and government agencies.Government agencies use genetic testing services to evaluate drugs for regulatory compliance for public health monitoring and research initiatives.Academic and research institutions a

249、re integral to the North America genetic testing services market.They help in identifying genetic markers,developing new genetic testing methodologies,and improving existing tests.These institutions validate and ensure the quality of genetic tests through rigorous studies,establishing their reliabil

250、ity and credibility.Clinical trials and studies conducted by these institutions provide essential evidence on the clinical utility and effectiveness of genetic tests.Their expertise and research efforts advance the growth of the market,benefiting both patients and healthcare providers.In addition,re

251、search and academic institutes are among the leading users of genetic testing services.Academic institutes for medical sciences and biotechnology utilize analytical testing services to support their studies on drugs.Thus,the increasing demand for genetic testing services from government agencies and

252、 research institutes will likely continue to drive the North America genetic testing services market for the segment.8.5.2 Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Others segment was valued at US$169.83 million in 2022 and is expected to reach US$2

253、49.31 million by 2030.The growth rate of this segment is projected to be 4.9%during 20222030.Figure 19.Others:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Secondary Sources 152.89161.37169.83179.04188.95

254、199.45210.35221.35232.02241.67249.31202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 44 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.North America Genetic Testing Services Market-Country Analysis 9.1 North America Figure 20

255、.North America:North America Genetic Testing Services Market,by Key Country Revenue(2022)(US$Million)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1 North America Genetic Testing Services Market,by Country Figure 21.North America Genetic Testing

256、 Services Market,By Key Countries,2022 and 2030(%)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources NORTH AMERICA(2022)137.61 159.77 1,306.93 MexicoCanadaUS81.5%10.0%8.6%2022USCanadaMexico84.4%9.4%6.2%2030 45 North America Genetic Testing Services Marke

257、t,2020-2030 |The Insight Partners 9.1.1.1 US 9.1.1.1.1 Overview According to the Centers for Disease Control and Prevention(CDC),1,603,844 new cancer cases were diagnosed in 2020,with 602,347 cancer deaths in the US.For every 100,000 individuals,403 new cancer cases were reported.In the US,1,958,310

258、 new cancer cases and 609,820 cancer deaths are projected to occur in 2023.Additionally,as per the International Agency for Research on Cancer,new cancer incidences were projected to reach 30.2 million by 2040.Cancer is the second highest death-causing disease worldwide,after heart disease.Several t

259、ypes of cancers are inherited from one generation to another generation due to genes.Genetic tests help in providing information on risk factors associated with the development of cancers among individuals with a family history of cancers.Thus,genetic testing is extensively applicable to study its p

260、attern for prevention,treatment,and drug discovery.As per the estimates of the US Government Accountability Office published in October 2021,25 to 30 million people suffer from rare diseases in the country;nearly 50%of patients with rare diseases are children.Rare diseases are often the result of a

261、genetic mutation;it is estimated that 80%of rare diseases are genetic.Genetic testing has been an essential part of the healthcare industry in the US for the last few decades.With the increased adoption of genetic testing,there has been a need to look after the quality of the tests being conducted a

262、cross the US.Regulation of genetic testing laboratories has been undertaken by the Clinical Laboratory Improvement Amendments(CLIA),which extends federal regulation over nearly all US clinical laboratories.CLIA requires laboratories to participate in quality control and quality assurance schemes and

263、 requires laboratory inspections.Also,the quality of genetic testing kits that the clinical laboratory purchases from an external provider is regulated by the US FDA.The demand for genetic testing in the US is expected to witness growth since the service encompasses a broad range of applications,suc

264、h as cancer,autoimmune diseases,and infectious diseases.In the US,the products for genetic testing of pediatric as well as rare diseases have increased significantly.For instance,in July 2021,Avellino Labs launched AvaGen,the genetic eye test,in the US.The test is designed to determine the risk of k

265、eratoconus and other corneal dystrophies in patients.In February 2020,the US FDA authorized the marketing of the first genetic test to detect a condition known as Fragile X Syndrome,which is one of the common causes of inherited developmental delay and intellectual disability among people.Thus,innov

266、ation in product design,improvement in quality,and strong distribution partnerships help to retain a competitive edge in the market.Therefore,the presence of regulatory policies associated with the use and the sale of genetic testing products,the rising cases of rare and genetic diseases in the US,a

267、nd the development of innovative genetic testing products are anticipated to fuel the growth of the North America genetic testing services market during 20222030.9.1.1.1.2 US:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)The US genetic testing services market accou

268、nted for US$1,306.93 Mn in 2022 and it is expected to grow at a CAGR of 15.7%during the period 2022-2030,to reach US$4,208.99 Mn in 2030.46 North America Genetic Testing Services Market,2020-2030 |The Insight Partners Figure 22.US:North America Genetic Testing Services Market Revenue and Forecast to

269、 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1.1.3 US:North America Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 2.US:North America Genetic Testing Services Market,by Service Type Revenue and Forecast to

270、 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 398.46 453.93 517.53 593.60 684.90 794.95 928.12 1,089.97 1,287.52 1,529.69 1,827.92 17.1%Carrier Testing 246.43 278.42 314.87 358.27 410.13 472.36 547.30 637.94 748.00 882.25 1,046.

271、72 16.2%Prenatal Testing 135.55 151.44 169.35 190.54 215.67 245.60 281.34 324.21 375.82 438.21 513.93 14.9%Newborn Screening 158.60 178.64 201.40 228.45 260.72 299.36 345.81 401.85 469.77 552.42 653.45 15.9%Others 92.13 97.90 103.78 110.25 117.32 124.96 133.11 141.64 150.37 158.97 166.96 6.1%Source:

272、The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the predictive testing segment was worth US$517.53 million in 2022 and is projected to reach US$1,827.92 million by 2030;it is expected to grow at a CAG

273、R of 17.1%from 2022 to 2030.1,031.161,160.341,306.931,481.111,688.761,937.232,235.682,595.613,031.483,561.554,208.99202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 47 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.1.4 US

274、:North America Genetic Testing Services Market,by Disease,20202030(US$Million)Table 3.US:North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 453.33 516.31 588.51 674.84 77

275、8.46 903.32 1,054.41 1,238.01 1,462.07 1,736.71 2,074.86 17.1%Cardiovascular Diseases 228.08 258.32 292.84 333.99 383.24 442.41 513.78 600.23 705.37 833.83 991.45 16.5%Metabolic Diseases 200.88 224.00 249.99 280.70 317.07 360.31 411.87 473.60 547.78 637.27 745.69 14.6%Others 148.86 161.70 175.59 191

276、.58 209.99 231.19 255.62 283.78 316.26 353.74 396.98 10.7%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the cancer segment was worth US$588.51 million in 2022 and is projected to reach US$2,0

277、74.86 million by 2030;it is expected to grow at a CAGR of 17.1%from 2022 to 2030.9.1.1.1.5 US:North America Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 4.US:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Ser

278、vice Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Hospital-Based Laboratories 634.67 721.15 820.11 938.31 1,080.02 1,250.57 1,456.67 1,706.79 2,011.62 2,384.77 2,843.59 16.8%Diagnostic Laboratories 274.39 310.15 350.90 399.44 457.47 527.10 610.99 712.47 835.75 986.16

279、 1,170.48 16.3%Others 122.11 129.04 135.91 143.35 151.27 159.56 168.02 176.35 184.11 190.62 194.92 4.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the hospital-based laboratories segment wa

280、s worth US$820.11 million in 2022 and is projected to reach US$2,843.59 million by 2030;it is expected to grow at a CAGR of 16.8%from 2022 to 2030.48 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2 Canada 9.1.1.2.1 Overview The increasing incidences of cancer ha

281、ve resulted in a higher demand for genetic testing services and prenatal testing.According to the data published by Statistics Canada,233,900 people in the country were diagnosed with cancer in 2022,and it caused 85,100 cancer-related mortality.The most commonly diagnosed cancers in the Canadian pop

282、ulation are lung,breast,prostate,and colorectal.Additionally,in 2022,as per the Canadian Cancer Society,28,600 women were diagnosed with breast cancer,representing 25%of all new cancer cases in women in the country.It is also estimated that about one in eight Canadian women will develop breast cance

283、r during their lifespan.Since breast cancer is the second leading reason of cancer deaths,genetic testing for the BRCA1 and BRCA2 gene variants linked with an increased risk of breast cancer can identify mutations that increase an individuals risk of developing cancer with a genetic foundation.There

284、fore,it is expected that the incidences of cancer are likely to increase,which will fuel the demand for genetic testing services.Various regulatory authorities in the country also recommend prenatal and newborn genetic testing to prevent the underlying risks of various diseases at early life stages.

285、For instance,The Society of Obstetrics and Gynecology of Canada advises pregnant women to undergo a range of prenatal screening to identify the risk of pregnancies and determine specific chromosome abnormalities.Furthermore,various healthcare providers and private laboratories are including prenatal

286、 genetic testing in their diagnostic offerings,which is expected to increase the demand for noninvasive prenatal test kits in Canada.For instance,in October 2015,LifeLabs became the first laboratory in Canada to perform noninvasive prenatal tests in Canada.In addition,in June 2022,Devyser won a brea

287、kthrough contract in Canada for noninvasive fetal RHD testing.It is used to determine fetal RHD status from maternal plasma in early pregnancy.Thus,owing to the factors mentioned above,the market for genetic testing services is expected to grow over the years to come.9.1.1.2.2 Canada:North America G

288、enetic Testing Services Market Revenue and Forecast to 2030(US$Mn)The Canada genetic testing services market accounted for US$159.77 Mn in 2022 and it is expected to grow at a CAGR of 14.3%during the period 2022-2030,to reach US$466.20 Mn in 2030.Figure 23.Canada:North America Genetic Testing Servic

289、es Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 129.16143.59159.77178.87201.47228.29260.24298.43344.25399.45466.20202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 4

290、9 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.2.3 Canada:North America Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 5.Canada:North America Genetic Testing Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Serv

291、ice Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 48.92 55.12 62.15 70.49 80.43 92.31 106.56 123.72 144.48 169.69 200.44 15.8%Carrier Testing 30.25 33.80 37.80 42.54 48.15 54.84 62.82 72.40 83.93 97.86 114.78 14.9%Prenatal Testing 16.64 18.38 20.33 22.6

292、2 25.32 28.50 32.29 36.79 42.16 48.60 56.36 13.6%Newborn Screening 19.47 21.67 24.13 27.04 30.49 34.58 39.45 45.28 52.28 60.72 70.94 14.4%Others 13.88 14.62 15.36 16.18 17.09 18.07 19.12 20.24 21.39 22.56 23.69 5.6%Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Se

293、condary Sources The North America genetic testing services market for the predictive testing segment was worth US$62.15 million in 2022 and is projected to reach US$200.44 million by 2030;it is expected to grow at a CAGR of 15.8%from 2022 to 2030.9.1.1.2.4 Canada:North America Genetic Testing Servic

294、es Market,by Disease,20202030(US$Million)Table 6.Canada North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 57.36 64.54 72.67 82.32 93.81 107.53 123.98 143.78 167.71 196.7

295、5 232.14 15.6%Cardiovascular Diseases 29.15 32.51 36.30 40.77 46.07 52.38 59.91 68.92 79.76 92.85 108.72 14.7%Metabolic Diseases 24.66 27.22 30.07 33.41 37.36 42.02 47.54 54.10 61.94 71.32 82.60 13.5%Others 17.99 19.32 20.74 22.36 24.23 26.37 28.82 31.63 34.84 38.53 42.75 9.5%Source:The Insight Part

296、ners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the cancer segment was worth US$72.67 million in 2022 and is projected to reach US$232.14 million by 2030;it is expected to grow at a CAGR of 15.6%from 2022 to 2030.9.1

297、.1.2.5 Canada:North America Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 7.Canada:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20

298、222030)Hospital-Based Laboratories 79.49 89.05 99.83 112.60 127.76 145.84 167.46 193.43 224.73 262.63 308.70 15.2%Diagnostic Laboratories 33.68 37.58 41.96 47.13 53.27 60.57 69.28 79.72 92.27 107.42 125.80 14.7%Others 15.98 16.96 17.99 19.14 20.44 21.88 23.50 25.28 27.25 29.39 31.71 7.3%Source:The I

299、nsight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources 50 North America Genetic Testing Services Market,2020-2030 |The Insight Partners The North America genetic testing services market for the hospital-based laboratories segment was worth US$99.83 million in 2022 a

300、nd is projected to reach US$308.70 million by 2030;it is expected to grow at a CAGR of 15.2%from 2022 to 2030.9.1.1.3 Mexico 9.1.1.3.1 Overview As per the Global Cancer Observatory data 2020,29,929 new breast cancer cases were registered in the country,representing 15.3%of all new cancer cases.Accor

301、ding to a study,Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients,published in 2020,4700 new cases of ovarian cancer are diagnosed yearly in the country,causing 2,700 ovarian cancer-related mortality.Germline mutations in BRCA1/2 genes are present in 1318%of ovarian cancer c

302、ases.Genetic testing services are used to diagnose,treat,and monitor cancer.Mexico faces challenges regarding chronic and degenerative diseases and experiences changes in important demographic and epidemiological transitions that result in significant patterns of disease,disability,and death.Therefo

303、re,preventing these diseases has become a key strategy in order to improve the economy and health of the Mexican population.Therefore,for the Mexican government,genomic medicine became a priority as a means of finding new strategies to tackle common diseases.In 2000,strategic planning for genomic me

304、dicine was started,and in 2004,the Mexican Congress commenced the creation of a National Institute of Genomic Medicine.Furthermore,the Institute of Genomic Medicine is a joint project by the Independent National University of Mexico,the Secretariat of Health,the National Council of Science and Techn

305、ology,and the Mexican Foundation for Health.The aims of the Institute include genomics in economical methods of prevention,diagnosis,and treatment of disease.The goal also includes the plan to enhance genomics training and research,to educate the public,and to make available advances in technology.C

306、ompanies operating in the region undertake various strategic efforts that led to the growth of the market in Mexico.For instance,in October 2023,Mexican Biobank launched the countrys most complete genetic database so far.A study completed as a part of a joint venture between Mexicos Cinvestav UGA-La

307、ngebio and NDMs Wellcome Centre for Human Genetics has revealed an extremely rich tapestry of genetics revealing population histories and diverse genetic make-up of the countrys population.The study aims to reveal the relationship between genetics,migration,mating patterns,and the environment that h

308、as shaped the current diversity of the countrys population.Thus,due to the factors mentioned above,the market for genetic testing services in Mexico is anticipated to witness significant growth during 20222030.51 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.2

309、 Mexico:North America Genetic Testing Services Market Revenue and Forecast to 2030(US$Mn)Mexico genetic testing services market accounted for US$137.61 Mn in 2022 and it is expected to grow at a CAGR of 10.6%during the period 2022-2030,to reach US$309.06 Mn in 2030.Figure 24.Mexico:North America Gen

310、etic Testing Services Market Revenue and Forecast to 2030(US$Mn)Source:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,Secondary Sources 9.1.1.3.3 Mexico:North America Genetic Testing Services Market,by Service Type,20202030(US$Million)Table 8.Mexico:North America Genetic Tes

311、ting Services Market,by Service Type Revenue and Forecast to 2030(US$Million)Service Type 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Predictive Testing 48.09 52.54 57.38 62.98 69.45 76.95 85.64 95.72 107.44 121.07 136.95 11.5%Carrier Testing 29.74 32.30 35.07 38.27 41.96 46

312、.22 51.15 56.86 63.46 71.12 80.01 10.9%Prenatal Testing 13.38 14.32 15.32 16.47 17.79 19.30 21.03 23.01 25.28 27.89 30.87 9.2%Newborn Screening 15.66 16.98 18.42 20.08 22.00 24.21 26.76 29.71 33.13 37.09 41.68 10.8%Others 10.30 10.85 11.42 12.07 12.80 13.63 14.56 15.61 16.78 18.09 19.55 7.0%Source:T

313、he Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the predictive testing segment was worth US$57.38 million in 2022 and is projected to reach US$136.95 million by 2030;it is expected to grow at a CAGR of

314、 11.5%from 2022 to 2030.117.17126.99137.61149.87164.00180.31199.15220.92246.10275.27309.06202020212022202320242025202620272028202920302020-2030Historical YearBase YearForecast Year 52 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 9.1.1.3.4 Mexico:North America Genetic

315、 Testing Services Market,by Disease,20202030(US$Million)Table 9.Mexico:North America Genetic Testing Services Market,by Disease Revenue and Forecast to 2030(US$Million)Disease 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 CAGR(20222030)Cancer 52.03 57.08 62.59 68.97 76.36 84.93 94.87 106.43

316、 119.89 135.58 153.89 11.9%Cardiovascular Diseases 26.18 28.38 30.76 33.51 36.68 40.34 44.56 49.45 55.10 61.65 69.23 10.7%Metabolic Diseases 22.37 24.01 25.75 27.76 30.06 32.71 35.75 39.24 43.24 47.84 53.13 9.5%Others 16.59 17.53 18.51 19.62 20.89 22.33 23.96 25.80 27.87 30.19 32.81 7.4%Source:The I

317、nsight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the cancer segment was worth US$62.59 million in 2022 and is projected to reach US$153.89 million by 2030;it is expected to grow at a CAGR of 11.9%from 2022

318、to 2030.9.1.1.3.5 Mexico:North America Genetic Testing Services Market,by Service Provider,20202030(US$Million)Table 10.Mexico:North America Genetic Testing Services Market,by Service Provider Revenue and Forecast to 2030(US$Million)Service Provider 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029

319、2030 CAGR(20222030)Hospital-Based Laboratories 72.12 78.75 85.98 94.34 104.00 115.19 128.15 143.19 160.66 180.99 204.65 11.5%Diagnostic Laboratories 30.25 32.87 35.70 38.98 42.75 47.12 52.17 58.01 64.78 72.62 81.73 10.9%Others 14.80 15.37 15.93 16.55 17.24 18.00 18.83 19.72 20.67 21.66 22.68 4.5%Sou

320、rce:The Insight Partners Analysis,Primary Interviews,Magazines and Journals,and Secondary Sources The North America genetic testing services market for the hospital-based laboratories segment was worth US$85.98 million in 2022 and is projected to reach US$204.65 million by 2030;it is expected to gro

321、w at a CAGR of 11.5%from 2022 to 2030.53 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 10.Genetic Testing Services MarketIndustry Landscape 10.1 Overview The developments in the North America genetic testing services market have been characterized by organic and inorg

322、anic growth strategies.Various companies are focusing on organic growth strategies such as launches,expansion,enhancement,and relocation.Inorganic growth strategies witnessed in the market include mergers&acquisitions,partnerships,and collaborations.These activities have paved the way for the expans

323、ion of business and the customer base of market players.Additionally,growth strategies such as acquisitions and partnerships helped in strengthening their customer base and increase the product portfolio.The companies have maximized their growth with several inorganic strategies to enhance the marke

324、t value and position in the market.The organic developments hold 73.33%of the total strategic developments in the market.Whereas the inorganic strategies helped by 26.67%for the growth of the companies.10.2 Growth Strategies in North America Genetic Testing Services Market Figure 25.Growth Strategie

325、s in North America Genetic Testing Services Market Source:The Insight Partners Analysis 26.67%73.33%Inorganic StrategiesOrganic Strategies 54 North America Genetic Testing Services Market,2020-2030 |The Insight Partners 10.3 Organic Growth Strategies 10.3.1 Overview Various companies have adopted or

326、ganic growth strategies in genetic testing services market.Some of the activities that have helped the companies promote their growth are launches,expansion,relocation activities.23andMe Holding Co is among the companies that have been implementing organic strategies,which,in turn,have brought about

327、 various changes in the global health economics and outcomes research services market.The companies have utilized strategies such as new product launch to expand their geographic reach and capacity to cater to a large number of customers.Some of the organic developments are listed below.Table 11.Rec

328、ent Organic Growth Strategies in North America Genetic Testing Services Market CompanyCompany Month&YearMonth&Year CategoryCategory DescriptionDescription 23andMe Holding Co Nov-2023 Product Launch 23andMe Holding Co launched 23andMe+Total Health,a new membership that offers that provides clinical g

329、rade exome sequencing,biannual blood testing,and access to genetics-based clinical care.Illumina Inc.Nov-2023 Company News Illumina Inc.announced the launch of the Global Health Access Initiative.It is anticipated that the effort will help low-and middle-income nations have access to pathogen sequen

330、cing tools for public health.The program will address major international logistics and supply chain challenges and offer discounted pricing structures for Illuminas eligible sequencing products to qualified global health funding entities.It was developed with input from customers,funders,and market

331、 facilitators,including the nonprofit FIND.23andMe Holding Co Oct-2023 Product Launch 23andMe Holding Co launched Health Action Plan,a new digital tool that utilizes results from genetic reports,health history survey data,and blood and biomarker data to provide a tailored set of health recommendatio

332、ns to its members.CENTOGENE Oct-2023 Product Launch The company expanded its Multiomic Diagnostic Portfolio with incorporation of transcriptomic analysis.It allows to combine DNA sequencing,biochemical testing,and RNA sequencing to improve testing capability.NeoGenomics Inc Oct-2023 Product Launch N

333、eoGenomics Inc launched two new tests to expand its portfolio of cancer products including Early-stage Non-Small Cell Lung Cancer Panel and the Neo Comprehensive-Heme Cancers Panel.Quest Diagnostics Inc Jul-2023 Product Launch Quest Diagnostics Inc announced launch of first consumer-initiated genetic test,Genetic Insights.The test can be accessed at via its consumer health business.With the launch